Direct antitumour activity of zoledronic acid: Preclinical and clinical data

Clinical and Translational Oncology

Volumn 13, Issue 3, 2011, Pages 148-155

  Bosch Barrera, Joaquim ^a   Merajver, Sofía D ^b   Menéndez, Javier A ^a   Van Poznak, Catherine ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Bisphosphonate; Bone metastasis; Mevalonate pathway; Translational oncology; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; HYPERCALCEMIA; IC 50; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOLOGIC FRACTURE; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SOFT TISSUE TUMOR; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; NEOPLASMS;

EID: 79958182023     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0634-9     Document Type: Review

References (94)

1. Ross JR, Saunders Y, Edmonds PM et al (2003) Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 327:469
2. Ricciardi S, de Marinis F (2009) Treatment of bone metastases in lung cancer: the actual role of zoledronic acid. Rev Recent Clin Trials 4:205-211
3. Clezardin P (2005) Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31[Suppl 3]:1-8
4. Santini D, Caraglia M, Vincenzi B et al (2006) Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates. Nat Clin Pract Oncol 3:325-338 (Pubitemid 43871543)
5. Neville-Webbe HL, Gnant M, Coleman RE (2010) Potential anticancer properties of bisphosphonates. Semin Oncol 37[Suppl 1]:S53-65
6. Santini D, Virzi V, Fratto ME et al (2010) Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets 10:46-54
7. Reeder JG, Brufsky AM (2010) The role of bisphosphonates in the adjuvant setting for breast cancer. Oncology (Williston Park) 24:462-7, 475
8. Gnant M (2009) Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr Cancer Drug Targets 9:824-833
9. Barginear MF, Van Poznak C (2010) Bisphosphonates: do we know their role in adjuvant breast cancer treatment? Oncology (Williston Park) 24:475, 478, 480
10. Neville-Webbe HL, Coleman RE (2010) Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 46:1211-1222
11. Lipton A (2008) Emerging role of bisphosphonates in the clinic: antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34[Suppl 1]:S25-30
12. Caccamo N, Meraviglia S, Scarpa F et al (2008) Aminobisphosphonate- activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther 8:875-883 (Pubitemid 352007000)
13. Meraviglia S, Eberl M, Vermijlen D et al (2010) In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 161:290-297
14. Vincenzi B, Santini D, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144-151 (Pubitemid 40354834)
15. Santini D, Vincenzi B, Galluzzo S et al (2007) Repeated intermittent low-dose therapy with zole-dronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 13:4482-4486 (Pubitemid 47219717)
16. Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744 (Pubitemid 37238631)
17. Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150-3157 (Pubitemid 46606297)
18. Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882 (Pubitemid 38807610)
19. Dunford JE, Thompson K, Coxon FP et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235-242 (Pubitemid 32112446)
20. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106 (Pubitemid 29322070)
21. Lawson MA, Xia Z, Barnett BL et al (2010) Differences between bisphosphonates in binding affinities for hydroxyapatite. J Biomed Mater Res B Appl Biomater 92:149-155
22. Russell RG, Watts NB, Ebetino FH et al (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733-759
23. Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88[Suppl 12]:2961-2978
24. Watts NB, Diab DL (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555-1565
25. Gennari L, Merlotti D, Mossetti G et al (2009) The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone. Mini Rev Med Chem 9:1052-1063
26. Phillipi CA, Remmington T, Steiner RD (2008) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev (4) (4):CD005088
27. Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 83:1032-1045
28. Lehenkari PP, Kellinsalmi M, Napankangas JP et al (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262 (Pubitemid 34441791)
29. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63:255-267
30. Rogers MJ, Frith JC, Luckman SP et al (1999) Molecular mechanisms of action of bisphosphonates. Bone 24 [Suppl 5]:73S-79S
31. Monkkonen H, Auriola S, Lehenkari P et al (2006) A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147:437-445 (Pubitemid 43292286)
32. Raikkonen J, Crockett JC, Rogers MJ et al (2009) Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 157:427-435
33. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15:2211-2221
34. Jagdev SP, Coleman RE, Shipman CM et al (2001) The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84:1126-1134 (Pubitemid 32448513)
35. Senaratne SG, Pirianov G, Mansi JL et al (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459-1468 (Pubitemid 30175914)
36. Verdijk R, Franke HR, Wolbers F et al (2007) Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 246:308-312 (Pubitemid 44959401)
37. Rachner TD, Singh SK, Schoppet M et al (2010) Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 287:109-116
38. Senaratne SG, Mansi JL, Colston KW (2002) The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86:1479-1486 (Pubitemid 34548073)
39. Oades GM, Senaratne SG, Clarke IA et al (2003) Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 170:246-252 (Pubitemid 36734471)
40. Ozturk OH, Bozcuk H, Burgucu D et al (2007) Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 31:1069-1071 (Pubitemid 46819059)
41. Koto K, Murata H, Kimura S et al (2010) Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 24:233-239
42. Denoyelle C, Hong L, Vannier JP et al (2003) New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 88:1631-1640 (Pubitemid 36713793)
43. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA et al (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364-371 (Pubitemid 40038702)
44. Chuah C, Barnes DJ, Kwok M et al (2005) Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia 19:1896-1904 (Pubitemid 41553997)
45. Monkkonen H, Ottewell PD, Kuokkanen J et al (2007) Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci 81:1066-1070 (Pubitemid 47418845)
46. Ory B, Blanchard F, Battaglia S et al (2007) Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71:333-343 (Pubitemid 46021003)
47. Fromigue O, Kheddoumi N, Body JJ (2003) Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer 89:178-184 (Pubitemid 36897955)
48. Stresing V, Daubine F, Benzaid I et al (2007) Bisphosphonates in cancer therapy. Cancer Lett 257:16-35 (Pubitemid 47464698)
49. Budman DR, Calabro A (2006) Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70:147-153 (Pubitemid 43760341)
50. Woodward JK, Neville-Webbe HL, Coleman RE et al (2005) Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 16:845-854 (Pubitemid 41215749)
51. Vogt U, Bielawski KP, Bosse U et al (2004) Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5- fluorouracil, epirubicin/cyclophosphamide, epirubicin/ paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 12:1109-1114
52. Matsumoto S, Kimura S, Segawa H et al (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47:31-39 (Pubitemid 39643239)
53. Benassi MS, Chiechi A, Ponticelli F et al (2007) Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 250:194-205 (Pubitemid 46529443)
54. Daubine F, Le Gall C, Gasser J et al (2007) Anti-tumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99:322-330 (Pubitemid 47073494)
55. Lamoureux F, Ory B, Battaglia S et al (2008) Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid. Int J Cancer 122:751-760
56. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623-633 (Pubitemid 39578752)
57. Wakchoure S, Merrell MA, Aldrich W et al (2006) Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 12:2862-2868
58. Gouin F, Ory B, Redini F et al (2006) Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119:980-984 (Pubitemid 44116903)
59. Ory B, Heymann MF, Kamijo A et al (2005) Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104:2522-2529 (Pubitemid 41691577)
60. Hiraga T, Williams PJ, Ueda A et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-4567 (Pubitemid 38878900)
61. Brubaker KD, Brown LG, Vessella RL et al (2006) Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6:15
62. Ottewell PD, Deux B, Monkkonen H et al (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 14:4658-4666
63. Ottewell PD, Monkkonen H, Jones M et al (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100:1167-1178
64. Lu S, Zhang J, Zhou Z et al (2008) Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 20:581-587
65. Heymann D, Ory B, Blanchard F et al (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37:74-86 (Pubitemid 40848420)
66. Zhou Z, Guan H, Duan X et al (2005) Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104:1713-1720 (Pubitemid 41437436)
67. Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567 (Pubitemid 32112871)
68. Rosen LS, Gordon DH, Dugan W Jr et al (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100:36-43 (Pubitemid 37553537)
69. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6:163-174
70. Dong M, Feng FY, Zhang Y et al (2008) Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma. Zhonghua Zhong Liu Za Zhi 30:215-220
71. Devitt B, McLachlan SA (2008) Use of ibandronate in the prevention of skeletal events in metastatic breast cancer. Ther Clin Risk Manag 4:453-458 (Pubitemid 351712003)
72. Costa L, Lipton A, Coleman RE (2006) Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 3:143-153 (Pubitemid 44022751)
73. Langer C, Hirsh V (2010) Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:4-11
74. Lipton A, Cook R, Saad F et al (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201 (Pubitemid 351976401)
75. Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860-1867 (Pubitemid 47557312)
76. Zaghloul MS, Boutrus R, El-Hossieny H et al (2010) A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15:382-389
77. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al (2009) The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 125:1705-1709
78. Pandya KJ, Gajra A, Warsi GM et al (2010) Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 67:330-338
79. Chen T, Berenson J, Vescio R et al (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228-1236 (Pubitemid 35205058)
80. Gao L, Deng H, Zhao H et al (2005) HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106:4294-4302 (Pubitemid 41775939)
81. Sato M, Grasser W, Endo N et al (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
82. Peng H, Sohara Y, Moats RA et al (2007) The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 67:9346-9355 (Pubitemid 47535924)
83. Winter MC, Syddall SP, Cross SS et al (2010) ANZAC: a randomised neoadjuvant biomarker study investigating the anti-tumour activity of the addition of zoledronic acid to chemotherapy in breast cancer. 33rd Annual San Antonio Breast Cancer Symposium. Abstract #P1-11-01
84. Zhao X, Xu X, Guo L et al (2010) Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat 124:733-743
85. Clyburn RD, Reid P, Evans CA et al (2010) Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 65:969-978
86. Neville-Webbe HL, Evans CA, Coleman RE et al (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 27:92-103
87. Morgan C, Lewis PD, Jones RM et al (2007) The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer. Acta Oncol 46:669-677 (Pubitemid 46911908)
88. Horie N, Murata H, Kimura S et al (2007) Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 96:255-261 (Pubitemid 46160630)
89. Ottewell PD, Lefley DV, Cross SS et al (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 126:522-532
90. Facchini G, Caraglia M, Morabito A et al (2010) Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. Cancer Biol Ther 10:543-548
91. Coleman RE, Thorpe HC, Cameron D et al (2010) Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). 33rd Annual Meeting of the San Antonio Breast Cancer Symposium. Abstract #S4-5
92. Gnant M, Eidtmann H (2010) The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more. Crit Rev Oncol Hematol 74[Suppl 1]:S2-6
93. Haque I, Mehta S, Majumder M et al (2011) Cyr61/CCN1 signaling is critical for epithelial-mesenchymal transition and stemness and promotes pancreatic carcinogenesis. Mol Cancer 10:8
94. Marra M, Santini D, Meo G et al (2009) Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 125:2004-2013